Neumora Therapeutics, a clinical-stage biopharmaceutical company specializing in brain diseases, has announced its plan to launch an initial public offering (IPO) to raise capital. Backed by Amgen, the company intends to sell 14.7 million shares at a price range of $16 to $18 per share. At the midpoint of $17 per share, Neumora expects to generate approximately $227.5 million … [Read more...] about Neumora Therapeutics Plans IPO
Footer
